OverviewSuggest Edit

ImmuPharma is a pharmaceutical company focused on developing innovative drugs to treat serious medical conditions in specialist therapeutic areas. Its low risk-strategy is to work closely with the largest fundamental research institutions, which allows access to scientists and doctors, keeping costs low by avoiding the constant funding necessary for early-stage research. The Company offers Lupuzor, a treatment for Lupus and its most advanced drug candidate.

TypePublic
Founded1999
HQLondon, GB
Websiteimmupharma.co.uk

Latest Updates

Employees (est.) (Feb 2021)17
Revenue (FY, 2018)£81.3 K(-45%)
Share Price (Mar 2021)£0.1 (+4%)
Cybersecurity ratingAMore

Key People/Management at ImmuPharma

Tim McCarthy

Tim McCarthy

Non-Executive Chairman
Robert Zimmer

Robert Zimmer

President, Chief Science Officer & Director
Dimitri F Dimitriou

Dimitri F Dimitriou

Chief Executive Officer, Co-Founder & Director
Stéphane Méry

Stéphane Méry

Non-Executive Director
Tim Franklin

Tim Franklin

Chief Operating Officer
Lisa Baderoon

Lisa Baderoon

Head of Investor Relations
Show more

ImmuPharma Office Locations

ImmuPharma has offices in London, Mulhouse and Sarnen
London, GB (HQ)
Terminal House, 52 Grosvenor Gardens, Belgravia
London, GB
1 Bartholomew Cl
Mulhouse, FR
5 Rue du Rhône
Sarnen, CH
10 Poststrasse
Show all (4)

ImmuPharma Financials and Metrics

ImmuPharma Revenue

ImmuPharma's revenue was reported to be £81.28 k in FY, 2018
GBP

Revenue (FY, 2018)

81.3k

Net income (FY, 2018)

(7.2m)

EBITDA (FY, 2018)

(7.9m)

EBIT (FY, 2018)

(8.1m)

Market capitalization (5-Mar-2021)

23.0m

Closing stock price (5-Mar-2021)

0.1

Cash (31-Dec-2018)

4.9m

EV

18.2m
ImmuPharma's current market capitalization is £23 m.
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

25.4k63.2k57.1k22.1m32.5k16.8k184.8k76.4k164.8k150.5k81.3k

Revenue growth, %

(59%)

Operating expense total

(1.5m)3.6m4.6m11.8m4.2m(3.8m)3.6m4.6m6.8m7.4m8.2m

EBITDA

(2.0m)(3.5m)(4.5m)10.3m(4.1m)3.9m(4.1m)(4.2m)(3.3m)(4.4m)(6.5m)(7.1m)(7.9m)
GBPFY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.01.01.0978.2k1.0m2.7m2.9m12.5m22.5m15.6m12.2m8.9m5.4m5.4m833.4k1.9m2.7m4.9m

Accounts Receivable

3.2k22.2k2.8k13.2k

Current Assets

1.01.01.0979.9k1.0m2.9m3.3m12.6m23.9m16.8m13.5m9.8m6.5m6.1m2.4m6.0m4.4m6.0m

PP&E

12.0k12.8k13.3k9.3k76.8k125.4k114.8k97.1k366.4k280.1k231.9k161.4k164.7k
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

1.4k15.1k(2.5m)(3.1m)4.7m8.1m(2.0m)(3.4m)(3.8m)(3.7m)(2.9m)(3.9m)(5.3m)(6.2m)(7.2m)

Cash From Operating Activities

15.8k18.3k879.6k3.8m(3.6m)12.0m(6.8m)(3.4m)(3.3m)(3.9m)(2.5m)(4.1m)(6.5m)(4.4m)(4.7m)

Cash From Financing Activities

977.0k3.0m(77.6k)12.0m(143.5k)555.2k165.3k356.9k191.5k3.0m(310.1k)7.4m5.4m9.1m

Net Change in Cash

978.2k27.1k2.7m3.7m8.5m11.9m(6.4m)(3.2m)(2.8m)(3.7m)199.0k(4.5m)896.3k945.9k2.3m
GBPFY, 2001

Financial Leverage

1 x
Show all financial metrics

ImmuPharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

ImmuPharma Online and Social Media Presence

Embed Graph

ImmuPharma News and Updates

Immupharma shares take off as firm signs US lupus deal

Specialist drug developer Immupharma rose almost 300 per cent today on the back of an exclusive US licensing deal for [...] The post Immupharma shares take off as firm signs US lupus deal appeared first on CityAM.

The Life Sciences Division Update Report on ImmuPharma plc Post AstraZeneca plc Announcement of Anifrolumab Successfully Navigating a Second Phase III Clinical Trial in Lupus

LONDON, Sept. 9, 2019 /PRNewswire/ -- The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announces an update report on ImmuPharma plc, a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on...

The Life Sciences Division Initiates Coverage on ImmuPharma Plc With a BUY/Corporate Rating

LONDON, May 28, 2019 /PRNewswire/ -- The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announces the initiation of research on ImmuPharma plc, a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on ...

ImmuPharma Blogs

Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update in respect to the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”), a potentially life-threatening auto-immune disease. …

Appointment of Company Secretary

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is pleased to announce that Ewa Flynn, the Company’s Financial Controller, was appointed as Company Secretary on 15 January 2021. To download announcement click here The post Appointmen…

ImmuPharma to present at Biotech Showcase™ Digital 2021

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that Dr Tim Franklin, ImmuPharma’s Chief Operating Officer, will be presenting at the prestigious Biotech Showcase™ Digital 2021. The event will be virtually held between 11 and 15 January 2021. As part of ImmuP…

Grant of Share Options & PDMR dealing

ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 9,625,000 ordinary shares of 10p each in the Company (“Ordinary Shares”) to Directors, employees and consultants representing 3.8% …

FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update on the announcement issued on 10 November 2020, in respect to the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”), a po…

Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients

ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces further regulatory and operational progress for the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”) a potentially life-threatenin…
Show more

ImmuPharma Frequently Asked Questions

  • When was ImmuPharma founded?

    ImmuPharma was founded in 1999.

  • Who are ImmuPharma key executives?

    ImmuPharma's key executives are Tim McCarthy, Robert Zimmer and Dimitri F Dimitriou.

  • How many employees does ImmuPharma have?

    ImmuPharma has 17 employees.

  • What is ImmuPharma revenue?

    Latest ImmuPharma annual revenue is £81.3 k.

  • What is ImmuPharma revenue per employee?

    Latest ImmuPharma revenue per employee is £4.8 k.

  • Who are ImmuPharma competitors?

    Competitors of ImmuPharma include Bracco, ProTab Laboratories and Akrivis Technologies.

  • Where is ImmuPharma headquarters?

    ImmuPharma headquarters is located at Terminal House, 52 Grosvenor Gardens, Belgravia, London.

  • Where are ImmuPharma offices?

    ImmuPharma has offices in London, Mulhouse and Sarnen.

  • How many offices does ImmuPharma have?

    ImmuPharma has 4 offices.